Mural Oncology's (MURA) shares jumped more than 160% in recent trading Tuesday after the company said it is discontinuing all clinical development of nemvaleukin alfa and plans to immediately start exploring strategic alternatives.
The move follows the review of data from its phase 2 ARTISTRY-6 trial in melanoma, which failed to achieve the primary endpoint, and previously announced adverse results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer, the Ireland-based clinical-stage immuno-oncology company said.
The company has engaged Lucid Capital Markets LLC as financial adviser for the exploration of strategic alternatives, which would include an offer for or other acquisition of the company, merger, or business combination. The company also said it will reduce its workforce by roughly 90%.
As of Dec. 31, 2024, the company had approximately $144.4 million of cash and cash equivalents, and marketable securities.
Price: 3.02, Change: +1.99, Percent Change: +193.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.